At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible.
For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.
A global leader in joint replacement, we offer a comprehensive portfolio of hip, knee and shoulder replacements, operating room products and bone cement and accessories.
We are the global leader in medical devices used to treat orthopaedic trauma. The company's fixation products, including screws, plates, nails and other implants, are used to treat fractures and deformities related to the extremities and pelvis.
Offering one of the most comprehensive portfolios of spinal care solutions in the world, treatment options are available in key areas including thoracolumbar, cervical, aging spine, interbody fusion and arthroplasty.
DePuy Synthes Mitek is a global leader in orthopaedic sports medicine devices and products used in the treatment of traumatic and degenerative soft tissue pathologies and joint injuries related to sports and physical activity.
We offer a comprehensive range of air, electric and battery-driven systems and associated dissections tools in three main areas: Large Bone, Small Bone and High Speed.
We are a global leader in cranio-maxillofacial devices, offering a comprehensive portfolio of products for surgeons to treat patients who have sustained conditions affecting their face, head, neck and thorax.
Providing a wide range of innovative products that complement the use of traditional metal implants in trauma, spine and cranio-maxillofacial surgical procedures, our biomaterials assist orthopaedic surgeons around the world with their mission to repair, protect and strengthen the structural core of the human body.
From creating the first sutures, to revolutionizing surgery with minimally invasive procedures, Ethicon* has made significant contributions to surgery for more than 100 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to address the world’s most pressing healthcare issues, and help improve and save more lives.
*Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates.
Ethicon offers the most complete energy portfolio for open and laparoscopic procedures. Our focus is to solve unmet surgical needs through our in-depth knowledge of tissue and energy sciences to help improve patient outcomes.
Ethicon remains a worldwide leader in the development of advanced tissue management, including surgical stapling and endocutter technologies. Ethicon provides surgeons with advanced instrumentation across the spectrum of surgical methods—all designed to support optimal patient outcomes. The wide range of options ensures the right solutions for the right procedures.
Our Ethicon portfolio of adjunctive hemostats is dedicated to aiding surgery by focusing on an array of biosurgery technologies to minimize intra- and postoperative complications. Solutions comprise innovative, biologically based products for surgical conditions that are often difficult or expensive to manage—such as problematic bleeding.
Every type of tissue, whether skin, fascia or organ, has its own specialized function and needs. Ethicon is leading advancements in wound closure that are transforming surgery. Our comprehensive wound closure portfolio lets surgeons match the specific wound healing needs of each tissue type to the appropriate closure device.
We develop, manufacture and market innovative, science-based products for surgical and non-surgical medical procedures that allow patients to improve their quality of life. Mentor Worldwide LLC is a leading supplier of medical products for the global aesthetic market. The company is focused on two strategic areas—breast and body aesthetics—and is the only manufacturer whose breast implants are made in the U.S.
Our Acclarent business is dedicated to developing innovative devices to meet the needs of patients suffering from ear, nose and throat (ENT) conditions, such as chronic sinusitis. Acclarent, Inc. is located in Irvine, California. Its singular focus is to free patients to live better lives by designing, developing and commercializing medical devices that address conditions affecting the ear, nose and throat. For more than a decade, Acclarent has led the field in delivering innovative technologies to ENT surgeons.
To treat patients with irregular heartbeats, hospitals and teaching institutions rely on advanced diagnostic, therapeutic and mapping tools from Biosense Webster, Inc. Biosense Webster is the global leader in the science of diagnosing and treating heart rhythm disorders. The company partners with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide.
Cerenovus is a global leader in neurovascular care. Our commitment to changing the trajectory of stroke is inspired by our long heritage and dedication to helping physicians protect people from a lifetime of hardship. Cerenovus offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke.
We bring together cutting-edge insights, science, technology and people to encourage professionals and patients to proactively preserve and enhance sight for life. And in communities with the greatest need, we collaborate to expand access to quality eye care.
Dual-headquartered in Jacksonville, Florida, and Santa Ana, California, we have more than 10,000 employees worldwide. Our eye health products are available in 103 countries.
Three brothers, Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson, founded Johnson & Johnson in New Brunswick, New Jersey, U.S.
Johnson & Johnson’s mass production of sterile sutures—along with sterile surgical dressings, cotton and gauze—ushers in the widespread practice of modern antiseptic surgery, dramatically raising survival rates.
Revra DePuy founded the DePuy manufacturing company, the world’s first orthopaedic company.
The Company expands to Argentina and Brazil. Ortho Research Laboratories, Inc. is established in Linden, New Jersey to make women’s health products.
Ethicon Suture Laboratories, formed in 1949 from the company’s heritage suture business, formed and became Ethicon, Inc.
Johnson & Johnson Vision Care, Inc. begins as Frontier Contact Lens Company in Buffalo, New York before eventually relocating to Jacksonville, Florida a few years later.
SURGICEL® Absorbable Hemostat sets a new standard for managing surgical bleeding—by helping to minimize blood loss.
The DePuy Synthes Companies of Johnson & Johnson begin their partnership with the AO Foundation to deliver world-class professional education and develop new innovations that improve patient outcomes and increase efficiency of care.
Ethicon introduces its first synthetic sterile suture, PROLENE® Polypropylene Suture, which remains the industry standard for cardiac bypass surgery for its strength, secure knotting and biocompatibility.
Ethicon’s game-changing skin stapler introduces disposable instruments to the operating room. Smaller and lighter than reusables, the PROXIMATE® disposable skin stapler offers improved visibility and easier use.
Adding a coating to the absorbable, polymer-based VICRYL® (polyglactin 910) Suture introduced in 1974, Ethicon shifted the global suture market. Innovations like VICRYL® Suture have helped cement Ethicon’s position as the worldwide leader in sutures.
DePuy introduces the LCS® Mobile Bearing Knee System. At the time, it is the only mobile bearing knee system approved for use in the United States.
Johnson & Johnson acquires Frontier.
The hip stem is now the world’s most widely used cementless femoral system, which features a bone-conserving surgical technique.
J&J Vision transforms vision correction and the eye care industry by introducing the world’s first disposable soft contact lenses under the name ACUVUE® Brand Contact Lenses.
With the first minimally invasive gall bladder removal, Ethicon maximized the potential of laparoscopic procedures. The company quickly began working with leading surgeons to identify minimally invasive surgical solutions.
The LIGACLIP® ERCA fully automatic clip appliers feature groundbreaking holding power, giving surgeons the confidence to adopt minimally invasive approaches.
J&J Vision offers eye health products and services to eye care professionals and patients in more places around the world by opening an operating group in Tokyo, Japan before further expanding to five continents within the year.
Ethicon opens its first Endo-Surgery Institute in Cincinnati, Ohio, to help surgeons master minimally invasive surgery techniques.
J&J Vision ACUVUE® Brand Contact Lenses become the #1 most prescribed contact lens brand in the world, helping people see better, connect better, live better.
J&J Vision revolutionizes its product portfolio by launching 1-DAY ACUVUE® Brand Contact Lenses, the world’s first daily disposable contact lens.
Ethicon hosts the first live telesurgery at the American College of Surgeons’ annual meeting, introducing clinicians to the possibilities of distance learning. Doctors witnessed the real-time broadcast from an off-site operating room.
UV Protection is adopted across the J&J Vision ACUVUE® Brand Contact Lenses portfolio, demonstrating the company’s longstanding commitment to continually raising standards of eye care.
Ethicon introduces the first 5mm HARMONIC® shears, enabling, for the first time, surgeons to dissect, cut and coagulate with one ultrasonic energy device, while also reducing thermal damage and preserving tissue function.
DERMABOND® Topical Skin Adhesive is introduced in the U.S., paving the way for replacing sutures with a new generation of skin closure solutions.
J&J Vision introduces ACUVUE® Brand Contact Lenses Bifocal, providing near vision correction to those with presbyopia.
J&J Vision ACUVUE Brand Contact Lenses introduces their INVISIBLE EDGE™ Design to help the eyelid glide seamlessly across the lens, helping to enhance comfort. The design is implemented across the ACUVUE® Brand Contact Lenses product portfolio.
Entering the new millennium, Ethicon committed to entering a multi-front assault against obesity. Our investment has created groundbreaking research in metabolic science, advanced bariatric training and standards.
The PINNACLE® Acetabular Cup System replaces the natural hip socket (acetabulum) and has since been provided for more than two million patients.
The first commercially available antibacterial suture, Coated VICRYL® Plus Antibacterial (polyglactin 910) Suture broke new ground in reducing surgical-site infections by preventing bacterial colonization of the suture.
The first VISION CARE INSTITUTE, LLC is established to provide eye care professionals and aspiring students with education, training and research opportunities. Today there are 15 Institutes across the global network.
DePuy begins selling ORTHOVISC© High Molecular Weight Hyaluronan, a multi-injection hyaluronan treatment used to treat knee pain due to osteoarthritis. ORTHOVISC© is a registered trademark of and manufactured by Anika Therapeutics.
J&J Vision ACUVUE OASYS® with HYDRACLEAR® PLUS Technology is launched, introducing a new lens wetting technology with increased moisture throughout. ACUVUE OASYS® will later introduce new options for people with astigmatism and presbyopia.
FDA approves Mentor’s MemoryGel™ Breast Implants in the U.S., representing the first approval of silicone gel implants by the FDA.
1-Day ACUVUE® MOIST Contact Lenses with LACREON® Technology are introduced, locking in the lenses’ wetting agent to provide wearers with a long-lasting cushion of moisture for exceptional comfort.
J&J Vision ACUVUE® Brand Contact Lenses become the first to receive the World Council of Optometry’s (WCO) Global Seal of Acceptance for UV Absorbing Contact Lenses.
J&J Vision ACUVUE OASYS® for Astigmatism launched using ACCELARATED STABILIZATION DESIGN™ (BLINK STABILIZED™ Design in the U.S.) to provide vision correction for those with astigmatism.
Mentor launches the CONTOUR PROFILE® Tissue Expander with suturing tabs (CPX3), the first of its kind.
J&J Vision 1-DAY ACUVUE® TruEye® with HYDRACLEAR® Technology launches in the United Kingdom, introducing the world to the first silicone hydrogel daily disposable contact lens. This technology enhances oxygen flow to the eye, providing superior comfort comparable to wearing no lenses.
Biosense Webster introduces CARTO® 3, the most advanced and most used 3D Cardiac Electro-anatomical Mapping System.
Biosense Webster launches THERMOCOOL SMARTTOUCH® SF Catheter.
Acclarent launches RELIEVA®Spin, a single-handed Balloon Sinuplasty device for in-office and operating room sinus surgery.
In a $21.3 billion transaction, the subsequent integration of the Synthes and DePuy businesses creates the world’s most comprehensive orthopedic and neurological company.
DePuy Synthes Companies launches the ATTUNE® Knee System, designed to help patients get back to what they enjoy sooner by optimizing how a patient’s knee replacement feels and moves.
The first purely ultrasonic device with a 7mm sealing indication, the breakthrough device combined precision and reliable sealing for large vessels. This dual-duty device allows surgeons to remain focused on the procedure.
Mentor’s extended gel breast portfolio with U.S. launch of shaped implants in U.S. supported by 10 years of clinical data.
EVARREST® Fibrin Sealant Patch is engineered to rapidly and reliably help surgeons stop bleeding in problematic situations when conventional methods are ineffective.
Important Safety Information
The MENTOR® ARTOURA™ Breast Tissue Expander is introduced and is the first expander with dynamic control technology for predictable expansion.
Strategic collaboration designed to develop new robotic technologies that offer surgeons and health care systems greater accuracy, cost efficiency and better outcomes for patients.
Ethicon acquired NeuWave Medical, Inc., a company that manufactures and markets soft tissue microwave ablation systems. This gave Ethicon a strong, minimally invasive entry into ablating soft tissue lesions.
The new company was formed by the strategic collaboration between Ethicon and Verily. In partnership with surgeons around the world, Verb Surgical aims to develop the next evolution in robotic surgery.
J&J Vision launches ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology, new technology for improved comfort and performance in challenging environments. The lens has tear-like properties that work with your natural tear film, providing all-day comfort and performance.
The TFN-ADVANCED® Proximal Femoral Nail System advances hip fracture treatment and solves a wide range of unmet needs for surgeons, OR staff and administrators treating people with these debilitating fractures.
J&J Vision ACUVUE® VITA Monthly Contact Lenses with HydraMax™ Technology are introduced to help maximize and maintain lens hydration for reliable, month-long comfort.
ACCLARENT AERA™ Eustachian Tube Balloon Dilation System is introduced. It’s the first FDA-approved device to safely and effectively treat Eustachian Tube Dysfunction (ETD) vs. medical management.
The Variable Angle Locking Hand System provides an extensive range of basic and specialty plates for fracture repair and deformity correction designed to reduce potential soft tissue irritation with the stability of locked plating.
Johnson & Johnson Medical Devices acquires Pulsar Vascular, a breakthrough platform technology for the neurovascular treatment of complex aneurysms.
Biosense Webster announces the U.S. approval of the THERMOCOOL SMARTTOUCH® SF Catheter. The catheter is the only approved device pairing contact force technology with a porous tip designed to optimize efficiency.
J&J acquires Abbott Medical Optics, gaining global leadership in ophthalmic surgery, including the #1 position in LASIK refractive surgery. J&J Vision able to offer broad range of eye health solutions to help eye care professionals and their patients through every stage of the lifetime eye health journey.
The VIPER PRIME® System for minimally invasive spine surgery combines multiple instruments into one tool and enables surgeons to target pedicles and insert screws in one single instrument pass, streamlining the procedure.
Ethicon’s acquisition of Megadyne Medical Products, Inc. brings together the intelligence of its advanced energy devices and Megadyne’s innovative portfolio of electrosurgical tools.
Ethicon’s acquisition of Torax allowed for investments in areas of unmet medical needs such as esophageal health. With its LINX® Reflux Management System, Ethicon is now able to provide surgical treatment for Gastroesophageal reflux disease. View safety information
Johnson & Johnson Medical Devices acquires Neuravi Limited, a company dedicated to advancing neurovascular therapies and improving clinical outcomes for acute ischemic stroke patients.
Johnson & Johnson Medical Devices Companies introduced CERENOVUS, its new neurovascular business.
J&J Vision launches the iDESIGN Refractive Studio, the first and only topo-integrated, wavefront-guided technology for LASIK.
Johnson & Johnson Medical Devices Companies acquired Orthotaxy, developer of a differentiated robotic surgery platform for orthopaedic procedures.
The ACTIS® Total Hip System is designed to increase joint stability immediately after hip replacement surgery and optimized for the Anterior Approach, which helps patients get back on their feet more quickly following surgery.
The KINCISE™ Surgical Automated System is a battery-powered device that automates key steps in total hip replacement surgery, leading to more consistent clinical outcomes, helping to reduce surgeon fatigue and the potential for work-related injuries.
This high-strength suture is uniquely designed to respond to changes in tension.
Ethicon improves the standard of care with a powdered version of its legacy adjunctive hemostat, SURGICEL® Original, to address a very common type of bleeding during surgery.
CERENOVUS receives 510(k) clearance from the FDA for EMBOTRAP II Revascularization Device, a next generation stent retriever used to capture and remove life-threatening blood clots from the brain following an ischemic stroke.
Acclarent launches TruDi, a real time, three-dimensional (3D) navigation system for ENT procedures performed in the operating room and surgeon office.
Johnson & Johnson launches ACUVUE® OASYS with Transitions™ Light Intelligent Technology™, the first-of-its-kind contact lens that seamlessly adapts to changing light, both revolutionizing the way contact lenses are worn and earning one of TIME’s Best Inventions of 2018.
Breakthrough innovation J&J Vision TECNIS® Eyhance IOL first lens in the monofocal IOL category in Europe to deliver improved intermediate vision and 20/20 distance vision; offers same, well-established low incidence of halo, glare, or starburst as TECNIS® 1-piece IOLs.
Auris Health’s robotic platform technology will enable Johnson & Johnson to deliver on the promise of digital surgery and drive better outcomes for patients.
Johnson & Johnson Companies launches CARTONET as part of the company’s mission to help revolutionize the way health systems leverage data with a goal of improving patient outcomes and operational efficiency in catheter ablation procedures.
The product offers advanced stapling technologies that target circular anastomosis, a critical step in surgery.
DePuy Synthes launched the SYMPHONY™ Occipito-Cervico-Thoracic (OCT) System, expanding its offering for the surgical treatment of conditions in the neck and upper back.